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Neopterin is associated with cardiovascular
events and all-cause mortality in renal
transplant patients
Pihlstrøm H, Mjøen G, M€arz W, Dahle DO, Abedini S, Holme I,
Fellstr€om B, Jardine A, Pilz S, Holdaas H. Neopterin is associated
with cardiovascular events and all-cause mortality in renal transplant
patients.
Abstract: Background: Inflammatory markers show significant
associations with cardiovascular events and all-cause mortality after
kidney transplantation. Neopterin, reflecting interferon-c-release, may
better reflect the proinflammatory state of recipients than less specific
markers.
Methods: Kidney transplant recipients in the Assessment of LEscol in
Renal Transplant (ALERT) trial were examined and investigated for an
association between serum neopterin and subsequent clinical events: graft
loss, major cardiovascular events (MACE) and all-cause mortality.
Results: After adjustment for established and emerging risk factors
neopterin expressed as neopterin-to-creatinine ratio was significantly
associated with MACE (p = 0.009) and all-cause mortality (p = 0.002).
Endpoints were more frequent with increasing quartiles of neopterin-to-
creatinine ratio. The incidence rates of MACE and all-cause mortality
were significantly increased in the upper quartiles compared with the first.
Conclusions: This long-term prospective analysis in stable kidney
allograft recipients suggests that neopterin is associated with long-term
risk of cardiovascular events and all-cause mortality, but not renal
outcomes.
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Cardiovascular (CV) events and premature deaths
are significantly more frequent in kidney transplant
recipients (KTR) compared with the general popu-
lation, even when adjusting for the higher preva-
lence of traditional risk factors such as diabetes
mellitus, hypercholesterolemia, and hypertension
(1). Although long-term statin therapy reduces the
incidence of major cardiovascular events (MACE)
in this population, there is significant residual risk
for both cardiac events and all-cause mortality (2).
Several non-traditional risk factors, both modifi-
able and non-modifiable, have been proposed to
contribute to this excessive risk (3). We have previ-
ously demonstrated in KTR with stable graft func-
tion that the inflammatory markers interleukin 6
(IL-6) and C-reactive protein (CRP) show signifi-
cant associations with CV events and all-cause
mortality (4). In this study, we explored the possi-
bility that neopterin may be a more appropriate
inflammatory marker for patients undergoing renal
transplantation (5).
Neopterin (D-erythro-1-2-3-trihydroxypropyl-
pterin) is produced from guanosine triphosphate
(6) by activated human monocytes, monocyte-
derived dendritic cells, and macrophages. Release
and production of neopterin is stimulated mainly
by interferon-c (IFN-c) released by activated Th1-
lymphocytes during the cellular immune response
(7). In contrast to IFN-c, which quickly binds to
target structures or is neutralized by soluble recep-
tors, neopterin is biochemical inert, and its serum
concentrations were closely linked to the activity
of the cellular immune system (8). Neopterin is
shown to be a marker of disease in a variety of con-
ditions (9) and has previously been associated with
CV events and mortality in non-transplant popula-
tions (10, 11). As a marker of cellular immune
response activation depending on IFN-c release,
neopterin may better reflect the proinflammatory
state of KTR than less specific markers of inflam-
mation, but the predictive value of neopterin for
clinical outcomes in stable KTR is unknown.
In the current analysis, long-term data from the
randomized Assessment of LEscol in Renal
Transplant (ALERT) trial (1) were examined to
investigate the association between serum neopter-
in level and subsequent adverse clinical outcomes
in a population of KTR.
Patients and methods
Study design
The study design and baseline data of the ALERT
trial have been described previously (12). In brief,
ALERT was a randomized, double-blind,
placebo-controlled study of the effect of fluvastatin
(40–80 mg/d vs. placebo) on cardiac and renal out-
comes in 2102 male and female KTR aged 30–
75 yr, included from June 1996 to October 1997.
Patients had received a renal transplant more than
six months previously, had a stable graft function
and a total serum cholesterol between 4.0 and
9.0 mM (155–348 mg/dL). Exclusion criteria were
familial hypercholesterolemia, recent acute rejec-
tion episodes, predicted life expectancy of less than
one yr or ongoing statin therapy. Follow-up was
5–6 yr in the core study, after which trial partici-
pants were offered open-label fluvastatin 80 mg/d
in a two-yr extension trial. Mean total follow-up
time for the extension study was 6.7 yr. Prior to
unblinding the ALERT study, neopterin was cho-
sen as one of the pre-specified cardiovascular risk
factors to be analyzed. Serum neopterin concentra-
tion was measured in 30% of patients (randomly
chosen) by radioimmunoassay (IBL Diagnostics,
Hamburg, Germany) in samples taken at the time
of study entry (baseline), a mean of 5.4 yr after
transplantation.
The study adhered to the International Confer-
ence on Harmonization guidelines for Good Clini-
cal Practice and was conducted in accordance with
the Declaration of Helsinki Principles. All partici-
pants provided written informed consent, and the
ethics committee at each participating center
approved the trial.
Outcome definitions
Renal endpoint was the time to graft loss (RGL),
defined as return to dialysis or retransplantation.
Cardiac endpoint was the occurrence of a MACE,
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defined as cardiac death, non-fatal myocardial
infarction verified by hospital records, or coronary
revascularization procedure, including coronary
artery bypass graft or percutaneous coronary inter-
vention. Death by any cause was also chosen as
study outcome. All endpoints were validated by an
independent clinical end point committee blinded
to study randomization.
Statistical analysis
Since treatment and placebo arms of the original
study showed no significant heterogeneity in rela-
tion to demographics, known cardiovascular or
renal risk factors or levels of inflammatory markers
(12), the current analysis was based on the pooled
patient population.
In comparing baseline characteristics between
groups, independent samples t-test and Mann–
Whitney U-test for continuous variables and chi-
square test for associations between categorical
variables were used. Spearman’s rank correlation
was used in checking for statistical associations
between neopterin and creatinine, as well as the
inflammatory markers IL-6 and CRP.
Univariable and multivariable Cox proportional
hazard models were used to evaluate the influence
of possible prognostic variables, including conven-
tional cardiovascular risk factors, other inflamma-
tory markers and factors associated with graft
survival. These models were used to examine the
association between neopterin and MACE, all-
cause mortality and graft loss. Since high sensitivity
CRP (hsCRP) and IL-6 are closely linked etiologi-
cally and considered to be mutual confounders, they
were included as covariates in separate multivari-
able regression models, the other variables remain-
ing the same. Covariates were examined using
Schoenenfeld residuals and found to fulfill the
assumptions of proportionality. Hazard ratios (HR)
were estimated with 95% confidence intervals.
Neopterin estimates
As neopterin is chemically inert and its elimination
is solely through the kidneys, compromised renal
function leads to a rise in serum neopterin that is
not caused by increased inflammatory activity (13).
We found a high degree of correlation between
neopterin and creatinine. Therefore, as done in the
majority of previous studies on neopterin in popu-
lations with compromised renal function, neopter-
in levels were calculated relative to the serum
concentration of creatinine, thus adjusting for kid-
ney function. Values are expressed in lmol/mol of
creatinine.
SPSS version 18 (IBM Corp., Armonk, NY,
USA) was used for all statistical analyses except for
generation of Figs. 1 and 2 where we used Stata
version 11 (StataCorp, College Station, TX, USA).
Results
Baseline characteristics
Table 1 lists baseline characteristics for the
ALERT participants, comparing those with and
without available baseline neopterin data. Demo-
graphics, risk factors, and neopterin levels were
similar in the fluvastatin and placebo arms (not
shown). Since there were no clinically important
differences, neither between the two treatment
arms nor between the overall study population and
those for whom neopterin levels were available –
subsequent analysis was performed on the pooled
population with available neopterin measurements
(4, 14).
Fig. 1. Cumulative all-cause mortality according to quartiles
of neopterin-to-creatinine ratio.
Fig. 2. Cumulative major cardiovascular events (MACE)
according to quartiles of neopterin-to-creatinine ratio.
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The correlation coefficient between neopterin
and creatinine was 0.61. For purposes of survival
analysis, we categorized patients into quartiles
according to their neopterin-to-creatinine ratios at
baseline. Levels ranged from 33 to 325 lmol/mol.
In Table 2, demographic data and background risk
factors are presented for each quartile of neopter-
in/creatinine. There was a tendency towards higher
proportions of patients with hypertension, chronic
heart disease, panel reactive antibodies, delayed
graft function (DGF), longer time on dialysis prior
to transplantation and treatment for CMV-infec-
tion/reactivation in the highest or the two highest
quartiles. IL-6 and hsCRP increased progressively
across the quartiles, as did age.
Outcomes
The proportions of patients reaching the renal, car-
diac and mortality endpoints in each quartile for
neopterin-to-creatinine ratio are listed in Table 3.
Log-rank tests were used to check the significance
of differences between each of the three upper
quartiles compared with the lowest.
The rate of death from all causes increased in
higher neopterin/creatinine quartiles, and the dif-
ferences were statistically significant between all
three upper quartiles and the first quartile. The
number of events more than trebled from the first
to the fourth quartile (9.5–33.6%). For MACE,
the incidence rate was more than twice as high
(11.1–25.0%) in the fourth neopterin/creatinine
quartile compared with the first one, and the differ-
ence was statistically significant. For renal graft
loss the incidence rates was slightly higher in the
fourth quartile, but no statistical significance was
reached.
Figs. 1 and 2 presents the Kaplan–Meier failure
estimates plots for all-cause mortality and MACE
showing time to event, or end of follow-up, by
neopterin/creatinine quartile.
Multiple risk factor analysis
Table 4 shows risk factor evaluation using univari-
able and multivariable models of Cox regression
analyses. For all study outcomes we present HR
with 95% confidence intervals (95% CI) and their
respective p-Values. In the univariable model,
baseline neopterin expressed as neopterin-to-creati-
nine ratio, as well as potential risk factors and
baseline demographics, is examined separately
against the study outcomes. The multivariable
model is adjusted for the following baseline covari-
ates: age, gender, smoking habit, diagnosis of coro-
nary heart disease, LDL-cholesterol, systolic blood
pressure, diabetes mellitus, serum creatinine, and
proteinuria. IL-6 and hsCRP were included in sep-
arate models, as they are part of the same etiologi-
cal inflammatory pathway and thus have a high
colinearity. Results are shown only for the analysis
including hsCRP, as the hazard ratio for neopterin
was virtually identical in the two models.
In the univariable model, neopterin was highly
significantly associated with all endpoints in our
study. After adjustment for other established and
potentially important risk factors, we found neop-
terin (in lmol/mol creatinine) to have a significant
positive association with all-cause of death (HR
1.06 per 10 units, p = 0.002, 95% CI 1.02–1.09)
and MACE (HR 1.06 per 10 units, p = 0.009, 95%
CI 1.01–1.10) but no independent predictive value
for graft loss. HR and p-Values for neopterin
remained the same for all endpoints when random-
ization group was included in the multivariate
model (not shown). Though reaching significance
for MACE in the univariable analyses, HsCRP
was not independently associated with any of the
Table 1. Demographic and baseline data for patients with or without
measurement of neopterin
Variables
Available
data (n)
Neopterin
measured
(n = 629)
Neopterin not
measured
(n = 1473)
Age at baseline, yr 2102 49.9 (10.9) 49.6 (10.9)
Male gender 2102 420 (66.8) 967 (65.6)
Current smoker 2100 133 (21.1) 256 (17.4)
Body mass
index, kg/m2
2051 25.5 (4.3) 25.9 (4.6)
Diabetes mellitus 2101 133 (21.1) 263 (17.9)
Hypertension 2102 483 (76.8) 1092 (74.1)
Systolic blood
pressure, mmHg
2094 142.6 (19.0) 144.5 (18.8)
Diastolic blood
pressure, mmHg
2093 85.5 (9.3) 85.7 (10.4)
Coronary heart disease 2101 58 (9.2) 143 (9.7)
Serum creatinine, lM 2028 146.2 (51.6) 145.0 (53.6)
Proteinuria, g/24 h 1981 0.40 (0.76) 0.45 (1.11)
HDL cholesterol, mM 2017 1.33 (0.46) 1.34 (0.45)
LDL cholesterol, mM 2001 4.19 (1.01) 4.12 (1.02)
Triglycerides, mM 2028 2.26 (1.24) 2.19 (1.42)
hsCRP, mg/L 1910 3.70 (6.82) 3.85 (6.66)
IL-6, pg/mL 1751 3.05 (1.92) 2.85 (1.84)
Time since last
transplant, yr
2101 5.4 (3.5) 5.0 (3.4)
Time on dialysis, yr 2092 2.2 (3.6) 2.3 (3.4)
Cold ischemia
time, hours
1520 17.9 (7.3) 20.5 (7.8)
Panel reactive antibodies 1845 117 (20.4) 210 (16.5)
Delayed graft function 2063 93 (15.0) 272 (18.8)
Treatment for
cytomegalovirus
2030 86 (14.1) 200 (14.1)
Continuous variables are shown as mean (SD); categorical variables as n
(%).
HDL, high-density lipoprotein; LDL, low-density lipoprotein; hsCRP, high
sensitivity CRP; IL-6, interleukin-6.
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study endpoints in the multivariable analyses, nor
was IL-6. Using Spearman’s rank correlation, we
found the correlation coefficient between neopterin
and IL-6 to be 0.26, p < 0.001, while for neopterin
and CRP it was 0.14, p < 0.001. Among the
remaining risk factors entered into the model,
diabetes mellitus was strongly associated with all
outcomes, as was current smoking for all outcomes
but MACE. As might have been expected, coro-
nary heart disease was predictive of future MACE
and all-cause mortality, while serum creatinine and
level of proteinuria was significantly associated
with the renal endpoint. Also, LDL-cholesterol
was significantly associated with MACE.
Neopterin was also included in a multivariate
model with osteoprotegrin, asymmetric dimethyl-
arginine (ADMA), and symmetric dimethylargi-
nine (SDMA) to assess its independency of other
markers related to inflammation and endothelial
function. No relevant change in HR was seen, and
the association with MACE and all-cause death
remained highly significant (data not shown).
Table 2. Demographic and baseline data according to quartiles of neopterin-to-creatinine ratio
Variable
Neopterin/creatinine quartile lmol/mol
1 (n = 153)
33–68
2 (n = 152)
68–87
3 (n = 152)
87–109
4 (n = 152)
109–325
Age at baseline, yr 46.2 (10.0) 49.2 (10.6) 51.4 (10.6) 53.1 (11.0)
Male gender 111 (72.5) 106 (69.7) 94 (61.8) 97 (63.8)
Current smoker 40 (26.1) 29 (19.1) 34 (22.4) 27 (17.8)
Body mass index, kg/m2 24.9 (4.0) 25.8 (4.1) 25.8 (4.9) 25.6 (4.3)
Diabetes mellitus 28 (18.3) 39 (25.7) 26 (17.1) 39 (25.7)
Hypertension 115 (75.2) 106 (69.7) 121 (79.6) 128 (84.2)
Systolic blood pressure, mmHg 141.2 (18.6) 141.7 (18.5) 144.1 (19.6) 143.5 (19.5)
Diastolic blood pressure, mmHg 85.5 (9.4) 85.2 (9.2) 85.5 (9.0) 85.7 (9.8)
Coronary heart disease 8 (5.2) 11 (7.2) 10 (6.6) 26 (17.1)
Serum creatinine, lM 145.9 (52.4) 144.1 (48.5) 145.2 (19.6) 149.7 (56.4)
Proteinuria, g/24 h 0.44 (0.99) 0.34 (0.48) 0.34 (0.66) 0.49 (0.81)
HDL cholesterol, mM 1.39 (0.42) 1.33 (0.46) 1.35 (0.50) 1.22 (0.46)
LDL cholesterol, mM 4.30 (0.95) 4.20 (1.09) 4.14 (0.97) 4.10 (1.04)
Triglycerides, mM 2.09 (1.01) 2.23 (1.48) 2.27 (1.27) 2.46 (1.16)
hsCRP, mg/L 2.15 (5.26) 3.61 (7.66) 4.71 (7.40) 4.54 (6.81)
IL-6, pg/mL 2.50 (1.43) 2.74 (1.78) 3.25 (2.20) 3.85 (2.15)
Time since last transplant, yr 5.7 (3.6) 5.7 (3.1) 5.3 (3.2) 4.8 (3.9)
Time on dialysis, yr 1.8 (2.9) 1.9 (2.6) 2.5 (4.2) 2.8 (4.2)
Cold ischemia time, hours 17.8 (8.0) 17.6 (6.4) 18.4 (6.1) 17.9 (8.5)
Panel reactive antibodies 26 (19.1) 28 (20.4) 26 (18.3) 34 (24.3)
Delayed graft function 17 (11.4) 15 (9.9) 31 (20.5) 29 (19.5)
Treatment for cytomegalovirus 18 (12.2) 17 (11.6) 19 (12.8) 31 (20.9)
Neopterin, nM 8.26 (3.03) 11.14 (3.80) 14.21 (4.93) 23.35 (13.02)
Randomized to fluvastatin 83 (54.2) 73 (48.0) 75 (49.3) 81 (53.3)
Continuous variables are shown as mean (SD); categorical variables as n (%).
HDL, high-density lipoprotein; LDL, low-density lipoprotein; hsCRP, high sensitivity CRP; IL-6, interleukin-6.
Table 3. Event occurrence in stable renal transplant patients according to neopterin/creatinine quartiles
Endpoint
Neopterin/creatinine quartile lmol/mol
1 (n = 153)
33–68
2 (n = 152)
68–87
3 (n = 152)
87–109
4 (n = 152)
109–325
Graft loss, n (%) 31 (20.3) 25 (16.4) 29 (19.1) 35 (23.0)
p-Value – 0.426 0.987 0.238
MACE, n (%) 17 (11.1) 25 (16.4) 25 (16.4) 38 (25.0)
p-Value – 0.159 0.105 0.001
All-cause mortality, n (%) 13 (9.5) 25 (16.4) 33 (21.7) 51 (33.6)
p-Value – 0.043 0.001 <0.001
Data expressed as number of patients with the event in each quartile (%). MACE, major adverse cardiac event.
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Discussion
In this analysis of a large cohort of KTR from the
ALERT study, we have shown that the inflamma-
tory marker neopterin is significantly associated
with cardiovascular events and all cause mortality
in KTR, even after adjustment for conventional
and new risk factors.
In patients with pre-dialysis chronic kidney
disease (CKD), serum neopterin is elevated and
significantly correlated with markers of inflamma-
tion including hsCRP, IL-6, and IFN-c. (15). We
have shown previously that levels of IL-6 and
hsCRP are associated with cardiovascular end-
points and all-cause mortality following kidney
transplantation (4, 16). However, and of central
importance, this study shows that in KTR the
predictive power of neopterin was maintained after
adjustment for hsCRP and IL-6. In the multivari-
able analyses including neopterin, CRP and IL-6
failed to reach significance as independent predic-
tors of long-term outcomes. In addition, though
statistically significant, the correlations between
neopterin and these two inflammation markers
were weak ones. Our epidemiological data on the
predictive value of neopterin are in line with previ-
ous literature showing that neopterin rises quickly
after macrophage activation (17), is an excellent
marker for longer term activation of cellular
immunity during the maintenance phase, and
appear to remain relatively stable over time (18).
Inflammation is a key element of the develop-
ment of atherosclerosis, with T-lymphocytes and
monocyte-derived macrophages being detected in
atherosclerotic lesions. In accordance with our
results, studies have highlighted neopterin as a
useful marker for long-term risk of all-cause and
cardiovascular death in patients from diverse
populations, including individuals undergoing
coronary angiography (19), patients with stable
Table 4. Hazard ratios for neopterin-to-creatinine ratio (per 10 units in lmol/mol) with covariates in relation to outcomes in 628 stable renal trans-
plant patients by univariable and multivariable Cox regression analysis
Risk factors
MACE 106/628 All-cause mortality 122/628
Graft loss (death-censored)
124/628
Univariable analysis HR (95% CI) p-Value HR (95% CI) p-Value HR (95% CI) p-Value
Age 1.03 (1.01–1.05) 0.002 1.07 (1.05–1.09) <0.001 0.98 (0.96–0.99) 0.008
Male gender 1.51 (0.98–2.34) 0.064 1.05 (0.72–1.54) 0.792 1.42 (0.96–2.12) 0.083
Current smoking 1.03 (0.64–1.64) 0.917 1.55 (1.04–2.30) 0.030 2.02 (1.39–2.94) <0.001
Coronary heart disease 4.00 (2.55–6.27) <0.001 3.22 (2.09–4.99) <0.001 1.00 (0.52–1.90) 0.994
LDL-cholesterol 1.42 (1.18–1.69) <0.001 1.06 (0.88–1.26) 0.552 1.11 (0.92–1.32) 0.273
Systolic blood pressure 1.01 (1.00–1.02) 0.202 1.01 (1.01–1.02) 0.001 1.02 (1.01–1.02) 0.001
Diabetes mellitus 1.99 (1.32–2.99) 0.001 2.17 (1.49–3.16) <0.001 1.64 (1.11–2.43) 0.013
Creatinine 1.01 (1.00–1.01) 0.002 1.01 (1.00–1.01) <0.001 1.02 (1.02–1.02) <0.001
Proteinuria 1.22 (1.02–1.45) 0.030 1.23 (1.04–1.45) 0.015 2.23 (1.96–2.54) <0.001
hsCRP 1.03 (1.01–1.05) 0.004 1.02 (1.00–1.04) 0.062 1.01 (0.99–1.03) 0.331
Neopterin/creatinine 1.08 (1.04–1.12) <0.001 1.11 (1.07–1.14) <0.001 1.05 (1.01–1.09) 0.020
Risk factors
MACE 100/585 All-cause mortality 117/583
Graft loss (death-censored)
114/583
Multivariable analysis HR (95% CI) p-Value HR (95% CI) p-Value HR (95% CI) p-Value
Age 1.02 (1.00–1.04) 0.057 1.07 (1.05–1.09) <0.001 0.98 (0.96–1.00) 0.097
Male gender 1.54 (0.96–2.45) 0.073 0.90 (0.59–1.35) 0.596 0.92 (0.59–1.44) 0.723
Current smoking 1.00 (0.60–1.65) 0.990 1.75 (1.16–2.65) 0.008 1.71 (1.14–2.58) 0.010
Coronary heart disease 3.35 (2.06–5.46) <0.001 2.02 (1.27–3.19) 0.003 1.04 (0.51–2.11) 0.921
LDL-cholesterol 1.47 (1.22–1.77) <0.001 0.99 (0.83–1.19) 0.940 1.07 (0.89–1.28) 0.498
Systolic blood pressure 1.00 (0.99–1.01) 0.503 1.00 (0.99–1.01) 0.893 1.00 (0.99–1.01) 0.979
Diabetes mellitus 2.01 (1.31–3.10) 0.002 2.38 (1.60–3.55) <0.001 1.82 (1.20–2.79) 0.005
Creatinine 1.00 (1.00–1.01) 0.056 1.01 (1.00–1.01) <0.001 1.02 (1.01–1.02) <0.001
Proteinuria 1.08 (0.87–1.34) 0.508 1.09 (0.87–1.35) 0.456 1.88 (1.60–2.21) <0.001
hsCRP 1.02 (1.00–1.04) 0.127 1.01 (0.99–1.03) 0.343 1.01 (0.99–1.03) 0.526
Neopterin/creatinine 1.06 (1.01–1.10) 0.009 1.06 (1.02–1.09) 0.002 1.03 (1.00–1.08) 0.152
The multivariable analysis adjusts for relevant demographic covariates (age, gender), known renal/cardiovascular risk factors (smoking, coronary heart dis-
ease, LDL-cholesterol, systolic blood pressure, diabetes mellitus, creatinine, level of proteinuria), and the inflammation marker hsCRP.
CI, confidence interval; HDL, high-density lipoprotein; HR, hazard ration; hsCRP, high sensitivity CRP; LDL, low-density lipoprotein; MACE, major adverse
cardiac event.
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coronary artery disease (20), newly diagnosed dia-
betics (21), and dialysis-dependent CKD patients
(22). Furthermore, it has recently been shown that
elevated neopterin, but not CRP level, predicts left
ventricular dysfunction in patients with chronic
stable angina pectoris (23). A recent report from
the Hordaland study demonstrated that in elderly
patients, without pre-existing coronary heart dis-
ease, higher levels of neopterin are associated with
an increased risk of subsequent coronary events
(24). Chronic low-grade inflammation is one of the
main conditions associated with increased cardio-
vascular morbidity and mortality in patients with
CKD, especially those on dialysis (25). Thus, it is
not surprising that persistent inflammation, endo-
thelial dysfunction, and associated oxidative stress
in KTR (26) is reflected in progression of athero-
sclerosis (27) and adversely affects cardiovascular
outcomes (4). The significant association between
neopterin and outcomes was maintained even after
adjustment for markers of endothelial function
(SDMA, ADMA).
Immunologic responses to allografts involve
humoral and cellular components of both the
adaptive and innate immune system, the T-cell
playing a pivotal role in the initial recognition of
anti-self (28). The stronger association that we
found between neopterin and the clinical endpoints
than for other inflammatory markers may possibly
reflect the dominance of T-cell and macrophage
activation in the ongoing inflammatory status of
allograft recipients. Consistent with this, baseline
neopterin values were substantially higher in our
cohort compared with the general population (29)
and patients with known CV disease (18). This is in
harmony with earlier findings on clinically stable
KTR (30, 31).
In one of the earliest publications to assess levels
of neopterin in KTR (32), Margreiter et al. mea-
sured urinary neopterin daily during the early
post-operative period and found that acute rejec-
tion and early viral infection were preceded by a
rising or high level of urinary neopterin in 95%
and 100% of cases, respectively. They later
extended their data to include urinary neopterin
measurements in 294 kidney allograft recipients
(33). Subsequent studies by others have confirmed
that elevation of serum or urinary neopterin pre-
cedes the rise in creatinine by up to several days in
patients with acute early complications (34, 35),
and routine daily post-operative neopterin mea-
surements have been suggested for the early detec-
tion of immunologic complications in kidney
allograft recipients (36).
In the trial (33) conducted by Reibnegger and
colleagues, a high neopterin level in the early
post-transplant period was associated with a
higher risk of graft failure in the long term. In a
smaller cohort of patients, Grebe et al. (37)
observed that elevated neopterin levels following
transplantation were associated with inferior graft
and patient survival, while a recent prospective
study in 216 KTR showed an association between
higher levels of neopterin and acute rejection in the
first year of follow-up (38). Our population was
recruited five yr after transplantation and was clin-
ically stable with a reasonably good renal function.
Elevated neopterin was not significantly associated
with renal graft loss after adjusting for level of pro-
teinuria. While Grebe et al. (37) were primarily
interested in early post-transplant macrophage
activation associated with elevated neopterin, our
study suggests that in clinically stable allograft
recipients, serum neopterin is not independently
associated with renal graft failure and does not
add significantly to the prognostic information
given by the degree of proteinuria. Weimer et al.
(39, 40) reported significant associations between
neopterin concentration at one yr post-transplant
and the development of chronic rejection and
chronic allograft dysfunction within two yr, but
proteinuria was not included in their multivariable
analysis, possibly explaining this discrepancy.
A small study on children with primary nephro-
tic syndrome (41) showed a positive correlation
between serum neopterin levels and proteinuria in
patients with active disease. A link between neop-
terin levels and the progression rate in proteinuric
diabetic nephropathy has been demonstrated (42),
and one group (43) observed marked differences in
serum and urine neopterin levels among diabetic
patients with and without microalbuminuria. We
are not proposing that enhanced macrophage
activity is not an important factor in the develop-
ment of a dysfunctional renal allograft, but the
potential clinical value of neopterin with respect to
graft function may be limited as long as protein-
uria is considered a well established risk factor for
poorer long-term renal outcomes in kidney allo-
graft recipients (44, 45).
Reference ranges for neopterin are higher in the
healthy elderly population (>75 yr). Several studies
report rising neopterin levels from the age of 60–70
(46) or even earlier (47), probably reflecting the
involvement of cellular immunity in the aging pro-
cess, as well as the presence of low-grade inflam-
matory processes such as atherosclerosis,
neurodegeneration, or unrecognized evolving dis-
ease (autoimmunity or malignancy) (29). However,
we did not find significant differences in baseline
neopterin between different age groups, perhaps
because kidney transplants are not performed for
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the oldest CKD patients (recipients in our cohort
were aged 23.6–74.8 yr), and because comorbidity,
the immunological consequences of long-standing
uremia and the anti-allograft immune response
may overshadow the component of neopterin pro-
duction related to aging.
The strengths of this analysis are the prospective
controlled design, the long follow-up time, the
large patient cohort and the independent adjudica-
tion of all clinical endpoints. Potential limitations
of our study, however, merit consideration.
Although the results show a strong association
between neopterin and clinical outcomes, the data
do not prove a causal relationship. Residual con-
founding cannot be ruled out, though we have
carefully adjusted for a wide range of covariates in
our statistical models. Although neopterin may, at
present, not be a clinically useful single parameter
for risk prediction in KTR, it is conceivable that
neopterin could be valuable for multi-marker risk
prediction or for the evaluation of the clinical effi-
cacy of established treatments in this patient
group.
As in most large prospective trials, serum samples
were obtained at inclusion and not followed consec-
utively. The study population, a cohort selected for
entry into a clinical trial, is not necessarily fully rep-
resentative of the general renal transplant popula-
tion, although the qualitative relationships between
neopterin and the specified clinical outcomes are
likely to apply, at least for Caucasians. Mean neop-
terin values were not different for the two randomi-
zation groups, and there was no significant skewing
in the proportion of patients receiving fluvastatin in
each quartile of neopterin-to-creatinine ratio.
Entering treatment group as a covariate in the mul-
tiple regression analysis did not change the hazard
ratio for neopterin.
In conclusion, in clinically stable renal trans-
plant recipients there appears to be an independent
association between serum neopterin concentration
and long-term clinical outcomes of MACE and all-
cause mortality.
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